• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

    8/21/25 10:17:14 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STTK alert in real time by email

    – SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –

    – The Company is on track to dose the first participant in its Phase 1 SL-325 clinical trial in healthy volunteers in Q3 2025 –

    – Current cash and cash equivalents, plus the anticipated aggregate proceeds of up to $103 million from recent private placement, assuming full exercise of common stock warrants, expected to fund operations into 2029 –

    AUSTIN, TX and DURHAM, NC, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that the Company's Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) for SL-325 for the treatment of inflammatory bowel disease is in effect. SL-325, a potentially first-in-class DR3 blocking antibody, is a fully Fc-silenced humanized immunoglobulin G monoclonal antibody, demonstrated high-affinity binding to human DR3 and potent inhibition of TL1A binding to DR3 in preclinical studies, and a favorable safety profile in non-human primate studies.

    Dosing of the first participant is expected this quarter, and enrollment of the Phase 1 clinical trial is expected to be completed in the second quarter of 2026. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) trial in healthy volunteers evaluating safety, tolerability, and pharmacokinetics. Data from the trial will guide the doses and schedule for potential evaluation in Phase 2 clinical trials.

    "An open IND marks a significant milestone as we continue to advance our lead asset, SL-325, and we are excited to begin collecting clinical data for the first DR3 blocking antibody tested in humans this quarter," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.

    About SL-325

    SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck's preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. Shattuck expects to commence a Phase 1 clinical trial in healthy volunteers in the third quarter of 2025.

    About Shattuck Labs, Inc.

    Shattuck Labs, Inc. (NASDAQ:STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory autoimmune diseases. Shattuck's expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a potential first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. 

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Shattuck's expectations regarding: the aggregate amount of proceeds to be received from the private placement, including whether the common stock warrants will be exercised and provide the Company with additional capital; the use of proceeds from the private placement; expectations regarding the timing for enrollment of and dosing of patients in the Phase 1 trial for SL-325; the anticipated timing for completion of the Phase 1 trial for SL-325; expectations regarding the results of the Phase 1 trial for SL-325; anticipated Phase 2 clinical trials for SL-325; and the time period over which our capital resources will be sufficient to fund the Company's anticipated operations. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Shattuck's filings with the Securities and Exchange Commission (SEC)), many of which are beyond the Company's control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility; expected results of the Company's preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of the Company's clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; Shattuck's expectations regarding the overall benefit of the strategic prioritization of its pipeline; liquidity and capital resources; and other risks and uncertainties identified in Shattuck's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent disclosure documents filed with the SEC. The Company claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The Company expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

    Investor & Media Contact:

    Conor Richardson

    Vice President of Investor Relations

    Shattuck Labs, Inc.

    [email protected]



    Primary Logo

    Get the next $STTK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STTK

    DatePrice TargetRatingAnalyst
    3/17/2025$4.00Outperform
    Leerink Partners
    10/2/2024$8.00 → $2.00Buy → Neutral
    Citigroup
    10/2/2024Buy → Hold
    Needham
    10/1/2024Buy → Neutral
    H.C. Wainwright
    6/17/2024Buy → Neutral
    BTIG Research
    8/31/2022$12.00Buy
    BTIG Research
    6/1/2022$13.00Buy
    Citigroup
    5/2/2022$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $STTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Stout Stephen was granted 12,805 shares, increasing direct ownership by 17% to 86,275 units (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    8/27/25 6:30:07 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Siegall Clay B was granted 128,054 shares (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    8/27/25 6:30:05 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technical Officer Shukla Abhinav A. was granted 5,122 shares, increasing direct ownership by 7% to 81,258 units (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    8/27/25 6:30:04 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

    — Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivalents, assuming full exercise of common stock warrants, expected to fund planned operations into 2029 — — Industry expert Dan Baker, M.D., and OrbiMed representative Mona Ashiya, Ph.D., appointed to the Board of Directors — AUSTIN, TX and DURHAM, NC, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily rece

    8/26/25 6:30:00 AM ET
    $IRON
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

    – SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to dose the first participant in its Phase 1 SL-325 clinical trial in healthy volunteers in Q3 2025 – – Current cash and cash equivalents, plus the anticipated aggregate proceeds of up to $103 million from recent private placement, assuming full exercise of common stock warrants, expected to fund operations into 2029 – AUSTIN, TX and DURHAM, NC, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a biotechnology company pioneering th

    8/21/25 10:17:14 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    – Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial for SL-325 in Q3 2025 – – Cash balance of approximately $50.5 million at end of Q2 2025 – – Aggregate proceeds from recent oversubscribed private placement of up to $103 million, less offering expenses, expected to fund operations into 2029 – AUSTIN, TX and DURHAM, NC, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TN

    8/14/25 6:30:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.

    SCHEDULE 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    8/26/25 5:01:01 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Shattuck Labs, Inc. (0001680367) (Filer)

    8/26/25 6:35:19 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Shattuck Labs Inc.

    10-Q - Shattuck Labs, Inc. (0001680367) (Filer)

    8/14/25 6:40:26 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Shattuck Labs with a new price target

    Leerink Partners initiated coverage of Shattuck Labs with a rating of Outperform and set a new price target of $4.00

    3/17/25 7:44:03 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs downgraded by Citigroup with a new price target

    Citigroup downgraded Shattuck Labs from Buy to Neutral and set a new price target of $2.00 from $8.00 previously

    10/2/24 7:58:39 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs downgraded by Needham

    Needham downgraded Shattuck Labs from Buy to Hold

    10/2/24 7:40:05 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Redmile Group, Llc sold $166,714 worth of shares (133,371 units at $1.25), bought $166,714 worth of shares (133,371 units at $1.25), disposed of $1,283,610 worth of shares (1,026,888 units at $1.25) and acquired $1,283,610 worth of shares (1,026,888 units at $1.25) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    12/6/24 9:00:15 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schreiber Taylor bought $44,220 worth of shares (36,500 units at $1.21), increasing direct ownership by 106% to 71,002 units (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    10/8/24 6:05:12 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Brous Tyler bought $32,768 worth of shares (8,416 units at $3.89), increasing direct ownership by 4% to 238,088 units (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    7/1/24 6:30:02 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Financials

    Live finance-specific insights

    View All

    Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

    – Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued –   – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – – Company to host investor call today at 8:00 AM Eastern Time (ET) – AUSTIN, T

    10/1/24 6:30:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

    – Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA – – Focuses clinical development opportunity in HR-MDS and TP53m AML; these indications may offer the fastest path to potential approval; enrollment underway in randomized, controlled HR-MDS co

    6/14/24 6:00:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

    - Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 Congress. The event will feature lead investigator, Dr. Naval G. Dave

    6/6/24 7:30:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Leadership Updates

    Live Leadership Updates

    View All

    Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

    AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre

    3/4/24 7:00:00 AM ET
    $IMNM
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

    AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023. Title: Shattuck Labs Third-Quarter 2023 Earnings Call Speakers: Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite, CMO Date & Time: Thursday, November 9, 2023 at 8:00 a.m. ET Dial-in Details: Toll-Free Dial-In Number: 1 (888) 440-4368 To

    11/6/23 9:28:40 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Changes to its Board of Directors

    AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors. Dr. Brownstein currently serves as the Chief Medical Officer at Cellectis. She will replace Josiah Hornblower, Shattuck's Chairman and founder, who is stepping down from the Board of Directors. George Golumbeski, Ph.D., has been appointed Chairman of the

    10/28/21 4:30:00 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

    SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

    11/13/24 8:30:26 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

    SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

    11/12/24 5:01:20 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care